m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05009
 [1]
Non-coding RNA H19 HNRNPA2B1  lncRNA       miRNA   circRNA Direct Enhancement m6A modification RAF1 RAF1 hnRNPA2B1 : m6A sites
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) READER
 Regulator Info 
m6A Target RAF proto-oncogene serine/threonine-protein kinase (RAF1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator H19 imprinted maternally expressed transcript (H19) LncRNA View Details
Regulated Target Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary H19 stabilized and upregulated the expression of RAF proto-oncogene serine/threonine-protein kinase (RAF1) by facilitated the interaction between HNRNPA2B1 and Raf-1 mRNA, resulting in activation of Raf-ERK signaling.Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
In-vitro Model
 HCT 116 Colon carcinoma Homo sapiens CVCL_0291
SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
In-vivo Model Mice were bred and maintained in a pathogen-free facility until the age of 6-week. 1 × 10^6 H19 overexpressed or control cells were suspended in 100 μL PBS and injected into the tail vein.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
RAF proto-oncogene serine/threonine-protein kinase (RAF1) 31 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Semapimod Phase 2 [2]
Synonyms
CPSI-2364; Semapimod (oral); Semapimod (oral), Cytokine PharmaSciences
    Click to Show/Hide
MOA Modulator
External Link
CID: 5745214
TTD: D01WKE
DrugBank: DB12094
 Compound Name BGB-3245 Phase 2 [3]
MOA Inhibitor
External Link
TTD: DMYS25
 Compound Name GDC-5573 Phase 1 [4]
Synonyms
RG6185
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0VS9E
 Compound Name Belvarafenib Phase 1 [5]
Synonyms
1446113-23-0; UNII-31M3WLJ3KG; 31M3WLJ3KG; 4-Amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-{1-[(3-chloro-2-fluorophenyl)amino]-6-methylisoquinolin-5-yl}thieno[3,2-d]pyrimidine-7-carboxamide; CHEMBL3977543; SCHEMBL15066408; BDBM185591; BCP31233; EX-A3061; s8853; HM95573; BS-15746; HY-109080; CS-0039257; Belvarafenib(GDC5573, HM95573, RG6185); US9156852, 116; 4-Amino-N-(1-(3-chloro-2-fluorophenylamino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide; 4-amino-N-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide; V1Y
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 89655386
TTD: DU98JH
 Compound Name MLN2480 Phase 2 [6]
Synonyms
VWMJHAFYPMOMGF-ZCFIWIBFSA-N; 1096708-71-2; MLN 2480; BIIB-024; Tak-580; MLN-2480; BIIB024; UNII-ZN90E4027M; BIIB 024; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-; ZN90E4027M; (r)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-n-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide; 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl]-; AMG 2112819
    Click to Show/Hide
External Link
CID: 25161177
TTD: D07IEU
DrugBank: DB15266
 Compound Name LXH254 Phase 1 [6]
Synonyms
UEPXBTCUIIGYCY-UHFFFAOYSA-N; SCHEMBL16094629; BDBM88120; HY-112089; CS-0043317; US9694016, 1156; 1800398-38-2; N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide
    Click to Show/Hide
Activity IC50 = 0.2 nM
External Link
CID: 90456533
TTD: D0T4QA
 Compound Name ICo-007 Phase 1 [6]
External Link
TTD: D0W2BK
 Compound Name LErafAON Phase 1 [6]
Synonyms
RafAON; Antisense raf oligonucleotide, NeoPharm; LErafAON, Insys; LErafAON-ETU; Liposomal antisense therapy, NeoPharm; Cancer therapeutic (antisense), NeoPharm; Liposome encapsulated c-raf antisense oligodeoxynucleotide, NeoPharm; Antisense oligonucleotides (liposome-encapsulated), NeoPharm
    Click to Show/Hide
External Link
TTD: D0W9QI
 Compound Name SPN-803 Phase 1 [6]
External Link
TTD: D02DXC
 Compound Name RG7304 Phase 1 [6]
External Link
CID: 74890577
TTD: D06EFW
 Compound Name ISIS 10707 Investigative [6]
External Link
TTD: D01KEF
 Compound Name ISIS 9058 Investigative [6]
External Link
TTD: D01LYK
 Compound Name 5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid Investigative [6]
Synonyms
CHEMBL216668
    Click to Show/Hide
Activity IC50 = 398 nM
External Link
CID: 44418518
TTD: D05UPS
 Compound Name ISIS 7853 Investigative [6]
External Link
TTD: D07JHY
 Compound Name ISIS 7855 Investigative [6]
External Link
TTD: D07QVR
 Compound Name ISIS 7851 Investigative [6]
External Link
TTD: D07XKC
 Compound Name ISIS 15770 Investigative [6]
External Link
TTD: D08KOD
 Compound Name ISIS 11061 Investigative [6]
External Link
TTD: D09IOO
 Compound Name ISIS 7848 Investigative [6]
External Link
TTD: D0E7WU
 Compound Name ISIS 6717 Investigative [6]
External Link
TTD: D0K5WH
 Compound Name ISIS 6720 Investigative [6]
External Link
TTD: D0LG0E
 Compound Name ISIS 6729 Investigative [6]
External Link
TTD: D0OV7O
 Compound Name ISIS 7849 Investigative [6]
External Link
TTD: D0Q1UM
 Compound Name L-790070 Investigative [6]
Synonyms
CHEMBL303144; 189442-43-1; MRK-48; SCHEMBL4025110; BDBM15459; CTK4E0131; DTXSID50430959; 4-[1-methyl-2-(piperidin-4-yl)-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-N-[(1S)-1-phenylethyl]pyridin-2-amine; 4-{1-methyl-2-piperidin-4-yl-4-[3-(trifluoromethyl)phenyl]-1H-imidazol-5-yl}-N-[(1S)-1-phenylethyl]pyridin-2-amine; 2-PYRIDINAMINE, 4-[1-METHYL-2-(4-PIPERIDINYL)-4-[3-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOL-5-YL]-N-[(1S)-1-PHENYLETHYL]-
    Click to Show/Hide
Activity IC50 = 810 nM
External Link
CID: 9806182
TTD: D0QN6U
 Compound Name ISIS 7847 Investigative [6]
External Link
TTD: D0R9BP
 Compound Name 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine Investigative [6]
Synonyms
SCHEMBL6660879
    Click to Show/Hide
External Link
CID: 44387948
TTD: D02TYK
 Compound Name PLX-ORI3 Investigative [6]
Synonyms
Omni-Raf inhibitors (cancer); Omni-Raf inhibitors (cancer), Plexxikon
    Click to Show/Hide
External Link
TTD: D06YMT
 Compound Name 6-Benzylsulfanyl-9H-purine Investigative [6]
Synonyms
Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine
    Click to Show/Hide
External Link
CID: 93558
TTD: D0BH7S
 Compound Name GW-5074 Investigative [6]
Synonyms
gw5074; 220904-83-6; GW 5074; Raf1 Kinase Inhibitor I; UNII-B7W8RS1GG2; B7W8RS1GG2; CHEMBL72365; 5-Iodo-3-[(3,5-dibromo-4-hydroxyphenyl)methylene]-2-indolinone; 3-(3,5-Dibromo-4-hydroxy-benzylidene)-5-iodo-1,3-dihydro-indol-2-one; (3Z)-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one; (Z)-3-(3,5-Dibromo-4-hydroxybenzylidene)-5-iodoindolin-2-one; SR-01000075897; STO521; 3-(3,5-Dibromo-4-hydroxybenzyliden)-5-iodo-1,3-dihydroindol-2-one; Tocris-1381
    Click to Show/Hide
Activity IC50 = 10.6 nM
External Link
CID: 5924208
TTD: D0Z5TQ
 Compound Name ZM-336372 Investigative [6]
Synonyms
ZM 336372; 208260-29-1; ZM336372; 3-(dimethylamino)-N-(3-(4-hydroxybenzamido)-4-methylphenyl)benzamide; N-[5-(3-Dimethylaminobenzamido)-2-methylphenyl]-4-hydroxybenzamide; CHEMBL186526; n-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide; 3-(dimethylamino)-N-{3-[(4-hydroxybenzoyl)amino]-4-methylphenyl}benzamide; 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide; 3-(dimethylamino)-N-[3-(4-hydroxybenzamido)-4-methylphenyl]benzamide; Bio1_001346; compound 1 [PMID: 15454231
    Click to Show/Hide
Activity IC50 = 70 nM
External Link
CID: 5730
TTD: D00NWF
 Compound Name DEBROMOHYMENIALDISINE Investigative [6]
External Link
CID: 135451156
TTD: D01WAI
DrugBank: DB04367
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [7]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
TTD: D0PG5O
 Compound Name Aflibercept Approved [8]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
TTD: D0C9ET
 Compound Name Regorafenib Approved [9]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
CID: 11167602
TTD: D09GDD
DrugBank: DB08896
 Compound Name Bevacizumab Approved [4]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name SYM-004 Phase 3 [4]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
TTD: D0CR8H
 Compound Name Bevacizumab + Erlotinib Phase 3 [10]
External Link
TTD: D09BKY
 Compound Name CPI-613 Phase 3 [4]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Bevacizumab Approved [8]
External Link
TTD: D0FX3U
 Compound Name AlloStim Phase 2/3 [11]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
TTD: D0B3CC
 Compound Name Sibrotuzumab Phase 2 [12]
External Link
TTD: DVX3H0
 Compound Name CV301 Phase 2 [13]
External Link
TTD: D9LT5G
 Compound Name Efatutazone Phase 2 [14]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9832447
TTD: D0Y8NZ
DrugBank: DB11894
 Compound Name LOR-2040 Phase 2 [15]
External Link
TTD: D0I7NG
 Compound Name RG7221 Phase 2 [16]
External Link
TTD: D06FTM
 Compound Name PEG-SN38 Phase 2 [17]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
CID: 59443782
TTD: D05UFP
 Compound Name MEGF0444A Phase 2 [18]
External Link
TTD: D01LES
 Compound Name Encapsulated cell therapy Phase 1/2 [19]
External Link
TTD: D0XY8C
 Compound Name AB928 Phase 1/2 [20]
External Link
CID: 135242184
TTD: D04UBI
 Compound Name MGD007 Phase 1 [16]
External Link
TTD: D00PEN
 Compound Name BNC-101 Phase 1 [21]
External Link
TTD: DD6AZ5
 Compound Name Navicixizumab Phase 1 [4]
External Link
TTD: D00IVN
 Compound Name RG7160 Discontinued in Phase 2 [22]
External Link
TTD: D0E2CQ
 Compound Name Nimesulide Terminated [23]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
CID: 4495
TTD: D0C0JT
DrugBank: DB04743
 Compound Name Saracatinib Phase 2 [24]
External Link
CID: 10302451
TTD: D05YTN
DrugBank: DB11805
 Compound Name G3139 + Irinotecan Investigative [25]
External Link
CID: 91865905
TTD: D05IAN
References
Ref 1 Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. J Exp Clin Cancer Res. 2020 Jul 22;39(1):141. doi: 10.1186/s13046-020-01619-6.
Ref 2 Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300.
Ref 3 Clinical pipeline report, company report or official report of BeiGene.
Ref 4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 5 Clinical pipeline report, company report or official report of Hanmi Pharmaceutical.
Ref 6 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 7 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 10 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 12 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 13 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 14 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 15 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 17 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 18 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 19 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 20 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 21 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 22 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 23 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 24 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 25 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.